Susanna Naggie

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
  2. doi request reprint Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    J Antimicrob Chemother 65:2063-9. 2010
  3. doi request reprint A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 124:276.e1-7. 2011
  4. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
  5. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
  6. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
  7. pmc Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e46029. 2012
  8. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
  9. pmc Management of hepatitis C virus infection: the basics
    Susanna Naggie
    Duke University School of Medicine, Durham, NC, USA
    Top Antivir Med 20:154-61. 2012
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010

Collaborators

Detail Information

Publications21

  1. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
    ..We investigate these polymorphisms in a cohort of human immunodeficiency virus (HIV)/HCV-coinfected patients...
  2. doi request reprint Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    J Antimicrob Chemother 65:2063-9. 2010
    ..Here, we summarize the current information regarding the effectiveness of protease inhibitors in treating chronic HCV and discuss the key challenges now facing the field...
  3. doi request reprint A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 124:276.e1-7. 2011
    ..The epidemiology of community-associated Clostridium difficile infection is not well known. We performed a multicenter, case-control study to further describe community-associated C. difficile infection and assess novel risk factors...
  4. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
    ..004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of IL28B genotype...
  5. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  6. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..Conclusion: Two ITPA variants were strongly associated with protection against treatment-related anemia in patients with genotype 2/3 HCV, but they did not decrease the need for RBV dose reduction or increase the rate of SVR...
  7. pmc Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e46029. 2012
    ..To determine the feasibility and case detection rate of a geographic information systems (GIS)-based integrated community screening strategy for tuberculosis, syphilis, and human immunodeficiency virus (HIV)...
  8. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  9. pmc Management of hepatitis C virus infection: the basics
    Susanna Naggie
    Duke University School of Medicine, Durham, NC, USA
    Top Antivir Med 20:154-61. 2012
    ..This article summarizes a basic review presented by Susanna Naggie, MD, at the IAS-USA live management of HCV continuing medical education program held in Atlanta in October ..
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  11. pmc Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection
    Brianna L Norton
    Duke University Medical Center, Durham, North Carolina 22710, USA
    AIDS Patient Care STDS 26:541-5. 2012
    ..This increase was not solely due to liver related events. Instead, comorbidities such as diabetes, renal disease, and psychiatric/substance abuse played a larger role in the health-care utilization in the HIV/HCV coinfected population...
  12. pmc Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 142:1324-1334.e3. 2012
    ..We review the latest developments and obstacles to treating coinfected patients...
  13. ncbi request reprint Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014
    Cody A Chastain
    Division of Infectious Diseases, Vanderbilt University Medical Center, A 2200 MCN, 1161 21st Avenue, Nashville, TN, 37232 2582, USA
    Curr HIV/AIDS Rep 10:408-19. 2013
    ..The management of adverse effects of HCV therapy and treatment considerations in patients with cirrhosis are also reviewed. ..
  14. doi request reprint Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis
    Susanna Naggie
    Division of Infectious Diseases, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Chest Med 30:337-53, vii-viii. 2009
    ....
  15. pmc Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States
    Anna K Person
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Patient Care STDS 24:539-43. 2010
    ..HIV testing was also widely accepted. Pairing QFT with opt-out HIV testing should be strongly considered when possible...
  16. doi request reprint Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    J Antimicrob Chemother 65:1094-9. 2010
    ..Here, we discuss the current recommendations and recent guidelines, and the evidence available for various PI-based ART regimens in treatment-naive patients. We also discuss adverse effects and the use of PIs in special circumstances...
  17. pmc Community-based HCV screening: knowledge and attitudes in a high risk urban population
    Brianna L Norton
    Division of Infectious Diseases and International Health, Duke University Medical Center, Box 102358, Durham, NC 27710, USA
    BMC Infect Dis 14:74. 2014
    ..Community-based screening may be one strategy in which to reach such persons; however, the acceptance of HCV testing, when many high-risk individuals may not have access to HCV specific medications, remains unknown...
  18. doi request reprint Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline
    Norma I Rallon
    Hospital Carlos III, Madrid, Spain bDuke Clinical Research Institute, Durham, North Carolina, USA
    AIDS 25:269-71. 2011
    ..No protective role of IL28B polymorphism was found examining both HIV-disease progression and HIV-protection...
  19. pmc An integrated alcohol abuse and medical treatment model for patients with hepatitis C
    Rae Jean Proeschold-Bell
    Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, 2812 Erwin Rd, 403, Durham, NC 27705, USA
    Dig Dis Sci 57:1083-91. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment...
  20. pmc Feasibility and willingness-to-pay for integrated community-based tuberculosis testing
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    BMC Infect Dis 11:305. 2011
    ..Community-based screening for TB, combined with HIV and syphilis testing, faces a number of barriers. One significant barrier is the value that target communities place on such screening...
  21. ncbi request reprint Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population
    Susan C Morpeth
    Duke University Medical Center, Durham, North Carolina, 27710, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
    AIDS Res Hum Retroviruses 23:1230-6. 2007
    ....